Why do ms patients have trouble walking

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Multiple sclerosis patients have trouble walking primarily due to demyelination of nerve fibers in the central nervous system, which disrupts electrical signal transmission. Approximately 85% of MS patients report walking difficulties as a key symptom, with mobility impairment often appearing within 5-10 years of diagnosis. Specific problems include muscle weakness (affecting 70-80% of patients), spasticity (present in 60-90%), and sensory deficits that impair balance and coordination. These walking impairments typically worsen during relapses or with disease progression, particularly in progressive forms of MS.

Key Facts

Multiple sclerosis affects approximately 2.8 million people worldwide as of 2020
Walking difficulties affect about 85% of MS patients at some point in their disease course
MS typically develops between ages 20-40, with diagnosis often occurring around age 30
Approximately 60-90% of MS patients experience spasticity that impairs walking
The annual relapse rate for relapsing-remitting MS is approximately 0.5-1.0 episodes per year

Overview

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, first described clinically by Jean-Martin Charcot in 1868. The disease involves the immune system attacking the protective myelin sheath that covers nerve fibers, causing communication problems between the brain and the rest of the body. MS affects approximately 2.8 million people globally as of 2020, with higher prevalence in temperate climates and among women (who are 2-3 times more likely to develop MS than men). The disease typically manifests between ages 20-40, with diagnosis often occurring around age 30. There are several clinical courses including relapsing-remitting MS (85% of initial diagnoses), secondary progressive MS, and primary progressive MS. The economic burden is substantial, with annual healthcare costs for MS patients in the United States averaging $30,000-$100,000 per patient depending on disease severity and treatment requirements.

How It Works

Walking difficulties in MS patients result from multiple neurological mechanisms working in combination. The primary mechanism is demyelination - the immune system attacks and damages the myelin sheath surrounding nerve axons in the brain and spinal cord. This disrupts the transmission of electrical signals along motor pathways that control leg movements. Specific impairments include: 1) Muscle weakness affecting 70-80% of patients due to disrupted signals from motor cortex to leg muscles; 2) Spasticity (muscle stiffness and involuntary spasms) affecting 60-90% of patients, caused by damage to upper motor neurons; 3) Sensory deficits including numbness, tingling, and impaired proprioception that affect balance and coordination; 4) Cerebellar dysfunction causing ataxia (uncoordinated movements) and tremors; 5) Fatigue affecting 80-90% of patients, which exacerbates walking difficulties. These mechanisms often interact, with damage occurring in multiple areas including the spinal cord (affecting leg control directly), cerebellum (affecting coordination), and cerebral hemispheres (affecting motor planning).

Why It Matters

Walking difficulties significantly impact MS patients' quality of life and independence. Mobility impairment affects daily activities, employment (with 60-80% unemployment rates among MS patients within 10 years of diagnosis), and mental health (depression affects approximately 50% of MS patients). Early walking problems often predict disease progression and disability accumulation, measured by the Expanded Disability Status Scale (EDSS). Effective management through physical therapy, assistive devices (used by 45-65% of patients), and disease-modifying therapies can preserve mobility. Research into neurorehabilitation and remyelination therapies continues, with recent advances in understanding how to promote neural repair. Maintaining walking ability remains a primary treatment goal, as preserved mobility correlates strongly with better long-term outcomes and reduced healthcare costs.